[18F] C05-05

[18F] C05-05 is a next-generation radiopharmaceutical developed as a positron emission tomography (PET) tracer for the in vivo detection and quantification of tau protein aggregates. Created by researchers at the National Institutes for Quantum Science and Technology (QST) in Japan, it is a fluorinated small molecule designed to overcome the limitations of first-generation tau tracers, such as [18F]flortaucipir. [18F] C05-05 exhibits high binding affinity and selectivity for a wide spectrum of tau filaments, including the 3R/4R isoforms found in Alzheimer's disease and the 4R isoforms characteristic of primary tauopathies like progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Its optimized pharmacokinetic profile includes high brain permeability and rapid washout from non-target tissues, which enhances the signal-to-noise ratio and allows for more sensitive imaging of tau pathology across various neurodegenerative disorders.

Other names

[18F]C05-05